Bellicum Pharmaceuticals, Inc. is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. Our lead product, BP-GMAX-CD1, is in Phase I clinical trials.

Bellicum is advancing the technology behind cellular immunotherapies with an activation platform powered to overcome the limits of current CAR-T treatments and impact more patients than ever.

Our GoCAR technology is designed to enhance T-cell proliferation and functional persistence, re-ignite host immunity, and overpower the suppressive tumor microenvironment to deliver the potential to treat solid tumors that traditional CAR-T therapies cannot reach.